Literature DB >> 15242576

Lack of efficacy of recombinant human thyrotropin versus thyroid hormone withdrawal for radioiodine therapy imaging in a patient with differentiated thyroid carcinoma lung metastases.

D Taïeb1, T Jacob, E Zotian, O Mundler.   

Abstract

The treatment of lung metastases of thyroid cancer is nearly exclusively limited to the administration of iodine-131. For patients presented with micronodular lesions, the therapeutic response is often excellent, increasing life expectancy. Because of the necessity of multiple iodine-131 treatments in the course of this therapy, and subsequently, the lack of tolerance of hormonal withdrawal, the use of recombinant human thyrotropin (rhTSH) as a method of stimulation could represent an interesting alternative. However, as in the present case, the stimulation by rhTSH can be less effective than hormonal withdrawal, as shown in the posttherapy scan to detect metastatic lesions and thus could be detrimental to the treatment efficiency.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15242576     DOI: 10.1089/105072504323150804

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  13 in total

1.  On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer.

Authors:  Paolo Zanotti-Fregonara; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12       Impact factor: 9.236

2.  Role of Recombinant Human Thyrotropin (rhTSH) in the Treatment of Well-Differentiated Thyroid Cancer.

Authors:  E Robenshtok; R Michael Tuttle
Journal:  Indian J Surg Oncol       Date:  2011-12-20

3.  Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.

Authors:  Joanna Klubo-Gwiezdzinska; Kenneth D Burman; Douglas Van Nostrand; Mihriye Mete; Jacqueline Jonklaas; Leonard Wartofsky
Journal:  Thyroid       Date:  2012-02-07       Impact factor: 6.568

4.  What role for recombinant human TSH in the treatment of metastatic thyroid cancer?

Authors:  Paolo Zanotti-Fregonara; Elif Hindié; Marie Elisabeth Toubert; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06       Impact factor: 9.236

5.  Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective.

Authors:  Paolo Zanotti-Fregonara; Domenico Rubello; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-10       Impact factor: 9.236

6.  Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT-Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer.

Authors:  Donika Plyku; Robert F Hobbs; Kevin Huang; Frank Atkins; Carlos Garcia; George Sgouros; Douglas Van Nostrand
Journal:  J Nucl Med       Date:  2017-01-19       Impact factor: 10.057

7.  The effect of lithium on the progression-free and overall survival in patients with metastatic differentiated thyroid cancer undergoing radioactive iodine therapy.

Authors:  Hongxiu Luo; Andrew Tobey; Sungyoung Auh; Craig Cochran; Marina Zemskova; James Reynolds; Cristiane Lima; Kenneth Burman; Leonard Wartofsky; Monica Skarulis; Electron Kebebew; Joanna Klubo-Gwiezdzinska
Journal:  Clin Endocrinol (Oxf)       Date:  2018-08-13       Impact factor: 3.478

Review 8.  Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.

Authors:  Chao Ma; Jiawei Xie; Wanxia Liu; Guoming Wang; Shuyao Zuo; Xufu Wang; Fengyu Wu
Journal:  Cochrane Database Syst Rev       Date:  2010-11-10

Review 9.  Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer.

Authors:  Joanna Klubo-Gwiezdzinska; Kenneth D Burman; Douglas Van Nostrand; Mihriye Mete; Jacqueline Jonklaas; Leonard Wartofsky
Journal:  Endocr Pract       Date:  2013 Jan-Feb       Impact factor: 3.443

10.  13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study.

Authors:  Daria Handkiewicz-Junak; Jozef Roskosz; Kornelia Hasse-Lazar; Sylwia Szpak-Ulczok; Zbigniew Puch; Aleksandra Kukulska; Tomasz Olczyk; Andrzej Piela; Ewa Paliczka-Cieslik; Barbara Jarzab
Journal:  Thyroid Res       Date:  2009-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.